Clinical Trial Update: Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of TA-8995 in healthy subjects with escalating doses; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• TA-8995

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Dyslipidemia | Phase 1 | Status: COMPLETED